Dechra has added to its anaesthesia and analgesia portfolio with the launch of the new anaesthetic and antiseptic gel, Tri-Solfen.
Licensed in the UK for local anaesthesia during and following castration of piglets and provision of castration wound antisepsis, Tri-Solfen contains four active ingredients in a single product to deliver multiple benefits.
These igredients include lidocaine and bupivacaine to deliver rapid onset and prolonged local anaesthesia effect, while adrenalin reduces blood loss and cetrimide lowers the risk of infection.
The gel is easy-to-administer and fast-acting (effective in just 30 seconds), providing a practical tool to improve animal welfare via cutaneous and epilesional use.
Tri-Solfen was originally developed and launched in Australia by Medical Ethics, a company that specialises in pain management treatments for humans and animals.
More than 100 million animals have been successfully treated with Tri-Solfen in Australia, New Zealand and Portugal, where it is licensed for disbudding, dehorning, castration and general wound treatments in cattle, sheep, pigs and horses.
“Tri-Solfen is widely used around the world for a variety of treatments,” comments Alana McGlade, MRCVS, national sales manager at Dechra.
“The introduction of Tri-Solfen to our extensive anaesthesia and analgesia range provides vets with exciting new options for local anaesthesia and animal welfare and it is a welcome addition to our product portfolio.”
For further information on Tri-Solfen please contact your local Dechra territory sales manager or visit their website.
